{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T15:30:28Z","timestamp":1792251028254,"version":"4.4.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2023,9,28]],"date-time":"2023-09-28T00:00:00Z","timestamp":1695859200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2023,9,28]],"date-time":"2023-09-28T00:00:00Z","timestamp":1695859200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs - Real World Outcomes"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1007\/s40801-023-00385-z","type":"journal-article","created":{"date-parts":[[2023,9,28]],"date-time":"2023-09-28T07:01:41Z","timestamp":1695884501000},"page":"631-637","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Efficacy of Three Teriparatide Preparations and Romosozumab, Osteogenesis Promoters, in the Treatment of Fresh Vertebral Fractures: A Retrospective Observational Study"],"prefix":"10.1007","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4544-3860","authenticated-orcid":false,"given":"Kouken","family":"Hayashi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,9,28]]},"reference":[{"key":"385_CR1","doi-asserted-by":"publisher","first-page":"1761","DOI":"10.1016\/S0140-6736(02)08657-9","volume":"359","author":"SR Cummings","year":"2002","unstructured":"Cummings SR, Melton LJ. Epidemiology and outcomes of osteoporotic fractures. Lancet. 2002;359:1761\u20137. https:\/\/doi.org\/10.1016\/S0140-6736(02)08657-9.","journal-title":"Lancet"},{"key":"385_CR2","doi-asserted-by":"publisher","unstructured":"NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy. Osteoporosis prevention, diagnosis, and therapy. JAMA. 2001;285:785\u201395. https:\/\/doi.org\/10.1001\/jama.285.6.785.","DOI":"10.1001\/jama.285.6.785"},{"key":"385_CR3","doi-asserted-by":"publisher","unstructured":"Matsumoto T, Hoshino M, Tsujio T, Terai H, Namikawa T, Matsumura A, et\u00a0al. Prognostic factors for reduction of activities of daily living following osteoporotic vertebral fractures. Spine (Phila Pa 1976). 2012;37:1115\u201321. https:\/\/doi.org\/10.1097\/BRS.0b013e3182432823.","DOI":"10.1097\/BRS.0b013e3182432823"},{"key":"385_CR4","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1016\/j.jos.2017.04.008","volume":"22","author":"S Takahashi","year":"2017","unstructured":"Takahashi S, Hoshino M, Tsujio T, Terai H, Suzuki A, Namikawa T, et\u00a0al. Risk factors for cognitive decline following osteoporotic vertebral fractures: a multicenter cohort study. J Orthop Sci. 2017;22:834\u20139. https:\/\/doi.org\/10.1016\/j.jos.2017.04.008.","journal-title":"J Orthop Sci"},{"key":"385_CR5","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1359\/jbmr.1999.14.5.821","volume":"14","author":"DM Black","year":"1999","unstructured":"Black DM, Arden NK, Palermo L, Pearson J, Cummings SR. Prevalent vertebral deformities predict hip fractures and new vertebral deformities but not wrist fractures. Study of Osteoporotic Fractures Research Group. J Bone Miner Res. 1999;14:821\u20138. https:\/\/doi.org\/10.1359\/jbmr.1999.14.5.821.","journal-title":"J Bone Miner Res"},{"key":"385_CR6","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1186\/s12891-017-1509-1","volume":"18","author":"A Iwata","year":"2017","unstructured":"Iwata A, Kanayama M, Oha M, Hashimoto T, Iwasaki N. Effect of teriparatide (rh-PTH 1\u201334) versus bisphosphonate on the healing of osteoporotic vertebral compression fracture: a retrospective comparative study. BMC Musculoskelet Disord. 2017;18:148. https:\/\/doi.org\/10.1186\/s12891-017-1509-1.","journal-title":"BMC Musculoskelet Disord"},{"key":"385_CR7","doi-asserted-by":"publisher","unstructured":"Kitaguchi K, Kashii M, Ebina K, Sasaki S, Tsukamoto Y, Yoshikawa H, et\u00a0al. Effects of weekly teriparatide administration for vertebral stability and bony union in patients with acute osteoporotic vertebral fractures. Asian Spine J. 2019;13:763\u201371. https:\/\/doi.org\/10.31616\/asj.2018.0311.","DOI":"10.31616\/asj.2018.0311"},{"key":"385_CR8","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1007\/s00774-019-01023-x","volume":"38","author":"S Ikeda","year":"2020","unstructured":"Ikeda S, Nakamura E, Narusawa K, Fukuda F, Matsumoto H, Nakai K, et\u00a0al. KOTU T-WRAP Study Investigators. Comparison of once-weekly teriparatide and alendronate against new osteoporotic vertebral fractures at week 12. J Bone Miner Metab. 2020;38:44\u201353. https:\/\/doi.org\/10.1007\/s00774-019-01023-x.","journal-title":"J Bone Miner Metab"},{"key":"385_CR9","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1007\/s00774-014-0646-y","volume":"34","author":"H Tsuchie","year":"2016","unstructured":"Tsuchie H, Miyakoshi N, Kasukawa Y, Nishi T, Abe H, Segawa T, et\u00a0al. The effect of teriparatide to alleviate pain and to prevent vertebral collapse after fresh osteoporotic vertebral fracture. J Bone Miner Metab. 2016;34:86\u201391. https:\/\/doi.org\/10.1007\/s00774-014-0646-y.","journal-title":"J Bone Miner Metab"},{"key":"385_CR10","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1007\/s00774-013-0441-1","volume":"31","author":"S Mori","year":"2013","unstructured":"Mori S, Soen S, Hagino H, Nakano T, Ito M, Fijiwara S, et\u00a0al. Justification criteria for vertebral fractures: year 2012 revision. J Bone Miner Metab. 2013;31:258\u201361.","journal-title":"J Bone Miner Metab"},{"key":"385_CR11","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1056\/NEJMoa1305224","volume":"370","author":"MR McClung","year":"2014","unstructured":"McClung MR, Grauer A, Boonen S, Bolognese MA, Brown JP, Diez-Perez A, et\u00a0al. Romosozumab in postmenopausal women with low bone mineral density. N Engl J Med. 2014;370:412\u201320. https:\/\/doi.org\/10.1056\/NEJMoa1305224.","journal-title":"N Engl J Med"},{"key":"385_CR12","doi-asserted-by":"publisher","unstructured":"Uemura T, Yano K, Takamatsu K, Miyashima Y, Yasuda H, Konishi S, et\u00a0al. Bone healing of distal radius nonunion treated with bridge plating with bonegraft substitutes in combination with systemic romosozumab administration: A case report. Jt Dis Relat Surg. 2021;32:526\u201330. https:\/\/doi.org\/10.52312\/jdrs.2021.82661.","DOI":"10.52312\/jdrs.2021.82661"},{"key":"385_CR13","doi-asserted-by":"publisher","first-page":"693","DOI":"10.2106\/JBJS.19.00790","volume":"102","author":"EH Schemitsch","year":"2020","unstructured":"Schemitsch EH, Miclau T, Karachalios T, Nowak LL, Sancheti P, Poolman RW, et\u00a0al. A randomized, placebo-controlled study of romosozumab for the treatment of hip fractures. J Bone Jt Surg Am. 2020;102:693\u2013702. https:\/\/doi.org\/10.2106\/JBJS.19.00790.","journal-title":"J Bone Jt Surg Am"},{"key":"385_CR14","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.2106\/JBJS.19.01008","volume":"102","author":"M Bhandari","year":"2020","unstructured":"Bhandari M, Schemitsch EH, Karachalios T, Sancheti P, Poolman RW, Caminis J, et\u00a0al. Romosozumab in skeletally mature adults with a fresh unilateral tibial diaphyseal fracture: a randomized phase-2 study. J Bone Jt Surg Am. 2020;102:1416\u201326. https:\/\/doi.org\/10.2106\/JBJS.19.01008.","journal-title":"J Bone Jt Surg Am"},{"key":"385_CR15","doi-asserted-by":"publisher","first-page":"2576","DOI":"10.1002\/jor.25287","volume":"40","author":"G Kim","year":"2022","unstructured":"Kim G, Inage K, Shiga Y, Mukaihata T, Tajiri I, Eguchi Y, et\u00a0al. Bone union-promoting effect of romosozumab in a rat posterolateral lumbar fusion model. J Orthop Res. 2022;40:2576\u201385. https:\/\/doi.org\/10.1002\/jor.25287.","journal-title":"J Orthop Res"},{"key":"385_CR16","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1056\/NEJM200105103441904","volume":"344","author":"RM Neer","year":"2001","unstructured":"Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY, et\u00a0al. Effect of parathyroid hormone (1\u201334) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med. 2001;344:1434\u201341. https:\/\/doi.org\/10.1056\/NEJM200105103441904.","journal-title":"N Engl J Med"},{"key":"385_CR17","doi-asserted-by":"publisher","first-page":"3097","DOI":"10.1210\/jc.2011-3479","volume":"97","author":"T Nakamura","year":"2012","unstructured":"Nakamura T, Sugimoto T, Nakano T, Kishimoto H, Ito M, Fukunaga M, et\u00a0al. Randomized Teriparatide [human parathyroid hormone (PTH) 1\u201334] Once-Weekly Efficacy Research (TOWER) trial for examining the reduction in new vertebral fractures in subjects with primary osteoporosis and high fracture risk. J Clin Endocrinol Metab. 2012;97:3097\u2013106. https:\/\/doi.org\/10.1210\/jc.2011-3479.","journal-title":"J Clin Endocrinol Metab"},{"key":"385_CR18","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1056\/NEJMoa1607948","volume":"375","author":"F Cosman","year":"2016","unstructured":"Cosman F, Crittenden DB, Adachi JD, Binkley N, Czerwinski E, Ferrari S, et\u00a0al. Romosozumab treatment in postmenopausal women with osteoporosis. N Engl J Med. 2016;375:1532\u201343. https:\/\/doi.org\/10.1056\/NEJMoa1607948.","journal-title":"N Engl J Med"},{"key":"385_CR19","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1002\/jbmr.2932","volume":"32","author":"HK Genant","year":"2017","unstructured":"Genant HK, Engelke K, Bolognese MA, Mautalen C, Brown JP, Recknor C, et\u00a0al. Effects of romosozumab compared with teriparatide on bone density and mass at the spine and hip in postmenopausal women with low bone mass. J Bone Miner Res. 2017;32:181\u20137.","journal-title":"J Bone Miner Res"},{"key":"385_CR20","doi-asserted-by":"publisher","first-page":"1585","DOI":"10.1016\/S0140-6736(17)31613-6","volume":"390","author":"BL Langdahl","year":"2017","unstructured":"Langdahl BL, Libanati C, Crittenden DB, Bolognese MA, Brown JP, Daizadeh NS, et\u00a0al. Romosozumab (sclerostin monoclonal antibody) versus teriparatide in postmenopausal women with osteoporosis transitioning from oral bisphosphonate therapy: a randomised, open-label, phase 3 trial. Lancet. 2017;390:1585\u201394.","journal-title":"Lancet"}],"updated-by":[{"DOI":"10.1007\/s40801-024-00429-y","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2024,5,21]],"date-time":"2024-05-21T00:00:00Z","timestamp":1716249600000}},{"DOI":"10.1007\/s40801-024-00421-6","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2024,4,6]],"date-time":"2024-04-06T00:00:00Z","timestamp":1712361600000}}],"container-title":["Drugs - Real World Outcomes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40801-023-00385-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40801-023-00385-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40801-023-00385-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,22]],"date-time":"2024-05-22T06:32:59Z","timestamp":1716359579000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40801-023-00385-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,28]]},"references-count":20,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["385"],"URL":"https:\/\/doi.org\/10.1007\/s40801-023-00385-z","relation":{"correction":[{"id-type":"doi","id":"10.1007\/s40801-024-00421-6","asserted-by":"object"},{"id-type":"doi","id":"10.1007\/s40801-024-00429-y","asserted-by":"object"}]},"ISSN":["2199-1154","2198-9788"],"issn-type":[{"value":"2199-1154","type":"print"},{"value":"2198-9788","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,28]]},"assertion":[{"value":"31 July 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 September 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 May 2024","order":3,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":4,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":5,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s40801-024-00429-y","URL":"https:\/\/doi.org\/10.1007\/s40801-024-00429-y","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 April 2024","order":7,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":8,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":9,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s40801-024-00421-6","URL":"https:\/\/doi.org\/10.1007\/s40801-024-00421-6","order":10,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This research was funded by Asahi Kasei Pharma Corporation. However, Asahi Kasei Pharma Corporation is not involved in data management or analysis.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"The author has no competing interests to declare that are relevant to the content of this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study was approved by the Yoyogi Mental Clinic Research Ethics Committee () on 21 October 2021 and conducted in accordance with the Declaration of Helsinki. Given the anonymity of the data, the informed consent requirement was waived.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"The consent was opted out via in-clinic posting.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}},{"value":"Data sharing not applicable to this article as no datasets were generated or analyzed during the current study.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"The author contributed to the conception and design of the study. The statistical analysis and first draft of the manuscript were prepared by Accerise, Inc., and the author prepared the final manuscript for submission.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}